Scichilone Nicola, Contino Adele, Figlioli Giovanni Battista, Paglino Giuseppe, Bellia Vincenzo
Dipartimento di Medicina, Pneumologia, Fisiologia e Nutrizione Umana (DIMPEFINU), University of Palermo, Palermo, Italy.
Patient Prefer Adherence. 2010 Feb 4;4:17-23. doi: 10.2147/ppa.s5627.
Asthma is a chronic inflammatory disorder of the airways that requires long-term treatment, the goal of which is to control clinical symptoms for extended periods with the least possible amount of drugs. International guidelines recommend the addition of an inhaled long-acting beta2-agonist (LABA) to a low- to medium-dose inhaled corticosteroid (ICS) when low doses of ICS fail to control asthma symptoms. The fixed combined administration of ICS/LABA improves patient compliance, reducing the risk of therapy discontinuation. The relative deposition pattern of the inhaled drug to the target site is the result of a complex interaction between the device used, the aerosol formulation and the patient's adherence to therapy. Different inhalation devices have been introduced in clinical practice over time. The new hydrofluoroalkane (HFA) solution aerosols allow for the particle size to be modified, thus leading to deeper penetration of the medication into the lung. The Modulite((R)) technology allows for the manipulation of inhaled HFA-based solution formulations, such as the fixed beclomethasone/formoterol combination, resulting in a uniform treatment of inflammation and bronchoconstriction. The success of any anti-asthmatic treatment depends on the choice of the correct device and the adherence to therapy.
哮喘是一种气道慢性炎症性疾病，需要长期治疗，其目标是以尽可能少的药物长期控制临床症状。国际指南建议，当低剂量吸入性糖皮质激素（ICS）无法控制哮喘症状时，应在低至中剂量ICS基础上加用吸入性长效β2受体激动剂（LABA）。ICS/LABA固定复方制剂可提高患者依从性，降低治疗中断风险。吸入药物在靶部位的相对沉积模式是所用装置、气雾剂剂型和患者治疗依从性之间复杂相互作用的结果。随着时间的推移，临床上引入了不同的吸入装置。新型氢氟烷烃（HFA）溶液气雾剂可调节颗粒大小，从而使药物更深入地渗透到肺部。Modulite((R))技术可操控基于HFA的吸入溶液制剂，如倍氯米松/福莫特罗固定复方制剂，从而实现对炎症和支气管收缩的均匀治疗。任何抗哮喘治疗的成功都取决于正确装置的选择和治疗依从性。
